Organisation paid for research Program year 2025 Source: CMS Open Payments

Alivation Research

Neither a doctor nor a teaching hospital

Research payments

$2,116,939

562 payments

Through program year 2025, Alivation Research is reported as receiving $2,116,939 in research payments, across 562 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$242,066	220
2024	Research	$129,403	102
2023	Research	$389,207	81
2022	Research	$618,264	92
2021	Research	$632,575	49
2020	Research	$104,004	17
2019	Research	$1,420	1

Breakdown

Who paid Research payments · program years 2019–2025

LivaNova USA, Inc. $1,958,891 504 payments
Jazz Pharmaceuticals Inc. $65,446 10 payments
GlaxoSmithKline, LLC. $61,862 31 payments
Supernus Pharmaceuticals, Inc. $15,987 6 payments
Teva Pharmaceuticals USA, Inc. $7,522 3 payments
Neurocrine Biosciences, Inc. $3,420 2 payments
H. Lundbeck A S $3,345 4 payments
AbbVie, Inc. $431 1 payment
Merck Sharp & Dohme Corporation $35 1 payment

Studies the money was for Research payments · program years 2019–2025

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression $952,478 62 payments
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER) $338,386 22 payments
(OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation $237,060 16 payments
Recover $192,861 263 payments
The RECOVERsUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes $177,663 35 payments
A Multicenter Phase 2 12-Week Double-Blind Placebo-Controlled Randomized Parallel-Group Study of Jzp150 for the Treatment of Posttraumatic Stress Disorder $65,446 10 payments
Phase 3B, Randomized, Observer-Blind. Multicenter Study to Assess the $61,862 31 payments
Osprey $38,505 31 payments
LivaNova UNCOVER $15,120 64 payments
A Phase IV, Open-Label, Flexible-Dose Safety Trial Evaluating Spn-812 Administered With Psychostimulants in Children and Adolescents (6 to 17 Years of Age) With Disorder (Adhd) Attention-Deficit/Hyperactivity $14,726 5 payments

What the money was spent on Research payments · program years 2019–2025

Patient care $14,501 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.